Verdence Capital Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$802K Buy
12,407
+61
+0.5% +$4.3K 0.05% 335
2025
Q4
$831K Sell
12,346
-679
-5% -$45.7K 0.05% 308
2025
Q3
$858K Sell
13,025
-512
-4% -$34K 0.05% 328
2025
Q2
$704K Sell
13,537
-64
-0.5% -$3.64K 0.05% 321
2025
Q1
$868K Buy
13,601
+370
+3% +$21.5K 0.07% 266
2024
Q4
$633K Sell
13,231
-1
-0% -$51 0.05% 319
2024
Q3
$757K Buy
13,232
+252
+2% +$14.4K 0.06% 301
2024
Q2
$680K Sell
12,980
-60
-0.5% -$2.63K 0.06% 302
2024
Q1
$530K Sell
13,040
-1,534
-11% -$57.5K 0.05% 338
2023
Q4
$539K Buy
14,574
+140
+1% +$5.27K 0.05% 322
2023
Q3
$551K Sell
14,434
-190
-1% -$7.78K 0.06% 310
2023
Q2
$527K Buy
14,624
+206
+1% +$7.03K 0.06% 308
2023
Q1
$551K Sell
14,418
-344
-2% -$16.1K 0.07% 292
2022
Q4
$840K Sell
14,762
-914
-6% -$46.8K 0.1% 203
2022
Q3
$620K Buy
15,676
+148
+1% +$6.54K 0.09% 236
2022
Q2
$683K Buy
15,528
+1,507
+11% +$65.2K 0.09% 235
2022
Q1
$559K Buy
14,021
+251
+2% +$8.94K 0.06% 280
2021
Q4
$554K Buy
13,770
+2,282
+20% +$85.2K 0.07% 272
2021
Q3
$467K Sell
11,488
-7
-0.1% -$293 0.06% 288
2021
Q2
$522K Sell
11,495
-36
-0.3% -$1.59K 0.07% 248
2021
Q1
$481K Sell
11,531
-20
-0.2% -$913 0.08% 230
2020
Q4
$493K Buy
11,551
+163
+1% +$5.86K 0.09% 210
2020
Q3
$299K Hold
11,388
0.07% 252
2020
Q2
$305K Hold
11,388
0.08% 239
2020
Q1
$205K Hold
11,388
0.06% 276
2019
Q4
$202K Hold
11,388
0.05% 310
2019
Q3
$177K Hold
11,388
0.05% 290
2019
Q2
$196K Hold
11,388
0.06% 276
2019
Q1
$183K Hold
11,388
0.05% 256
2018
Q4
$167K Hold
11,388
0.05% 228
2018
Q3
$207K Hold
11,388
0.05% 248
2018
Q2
$192K Hold
11,388
0.05% 274
2018
Q1
$223K Hold
11,388
0.05% 255
2017
Q4
$231K Buy
+11,388
New +$209K 0.06% 244

Other funds holding HALO

Verdence Capital Advisors's HALO Position: Q1 2026 in Review

Verdence Capital Advisors increased its Halozyme (HALO) stake by 0.49% in Q1 2026, buying an estimated $4.3K and bringing the position to 12,407 shares worth $802K. The position accounts for 0.05% of the portfolio, ranked #335.

Verdence Capital Advisors first reported a position in HALO in Q4 2017 and has held it in 34 quarters since. The position peaked at $868K in Q1 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Verdence Capital Advisors held 12,407 shares of Halozyme worth $802K as of Q1 2026.
  • Verdence Capital Advisors bought 61 Halozyme shares in Q1 2026, an estimated $4.3K.
  • Halozyme made up 0.05% of Verdence Capital Advisors's portfolio in Q1 2026, its #335 holding.
  • Verdence Capital Advisors first reported a position in Halozyme in Q4 2017 and has held it in 34 quarters since.
  • Verdence Capital Advisors's Halozyme position peaked at $868K in Q1 2025.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.